Aortobifemoral bypass--an enduring operation.
Aortobifemoral bypass (ABF) has been available as a method for treating patients with aortoiliac occlusive or aneurysmal disease for 40 years. ABF has been successful in alleviating the symptoms of claudication and critical ischemia. The long-term patency rates have been excellent with low operative morbidity and mortality. Major improvements have been made in indications, preoperative assessment and operative and postoperative care. With careful follow-up the natural history of a patient who undergoes ABF is known. Predicting outcome is now possible and a cost:benefit analysis can be made. ABF has proved to be a successful and enduring procedure.
Ameli
F M
FM
Department of Surgery, Wellesley Hospital, Toronto, Ont.
D000792:Angiography; D001011:Aorta / Q000601:surgery*; D001807:Blood Vessel Prosthesis / Q000592:standards / Q000639:trends; D003362:Cost-Benefit Analysis; D005263:Femoral Artery / Q000601:surgery*; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology; D011300:Preoperative Care; D016896:Treatment Outcome; D014654:Vascular Patency; D014656:Vascular Surgical Procedures / Q000191:economics / Q000592:standards* / Q000639:trends